GENELUX

Fact Sheet

GNLX

LISTED

NASDAQ

Initial Public Offering: FEBRUARY 26, 2023

GENELUX

QUICK REFERENCE

Genelux Corporation

NASDAQ: GNLX

www.GENELUX.com

BUSINESS SUMMARY

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux's discovery and development efforts revolves around the Company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

PIPELINE

Overview

We are dedicated to developing a pipeline of next-generation immunotherapies for patients suffering with aggressive and/or difficult-to-treat solid tumor types.
A robust clinical pipeline advancing two programs with significant potential:

- A Regional Program (ovarian cancer) with delivery into the abdominal cavity that maximizes pharmacokinetics & tumor tissue exposure
- A Systemic Program (solid tumors) with intravenous delivery which looks to maximize the addressable indications

TECHNOLOGY

Our Science

Genelux aims to provide an elegant therapeutic approach. Our oncolytic immunotherapy drug candidates are "off-the-shelf" personalized therapeutics. In other words, while we administer the same virus product to different patients, the cellular immune response generated is specific to the unique neoantigens in that patient. We believe that our approach may offer significant advantages over other approaches to anticancer treatments.

Oncolytic Immunotherapy

Oncolytic immunotherapy is the treatment of cancer with viruses that selectively replicate in tumors, but not in normal tissues, which kills cancer cells in two ways. First, oncolytic viruses replicate in the tumor cell until the cell "bursts", resulting in the lysis of tumor cells. Second, when the cancer cells die, they release tumor neoantigens, which are taken up by cells of the immune system and alert the body's T-cells to search and destroy other cancer cells in the body. This oncolytic process establishes long-term antitumor immunity to unleash the full potential of the body's immune system and improve outcomes for cancer patients.

Modulating the Tumor Microenvironment: Overcoming Chemoresistance

Olvi-Vec-primed immunochemotherapy delivers synergistic anti-tumor activities through multifaceted and complimentary mechanisms of action.

CONTACT INFORMATION

Headquarters
2625 Townsgate Road
Westlake Village, CA 91361

Barwicki Investor Relations
Andrew Barwicki
516-662-9461 / andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

Genelux Corporation Announces Pricing of Initial Public Offering

Jan. 25, 2023 -- Genelux Corporation, a clinical-stage immunotherapy company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types, announced the pricing of its initial public offering of 2,500,000 shares of its common stock at a price to the public of $6.00 per share, for total gross proceeds of approximately $15.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Genelux. In addition, Genelux has granted the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.

In connection with the offering, the Company's shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol "GNLX" on January 26, 2023 subject to final approval by Nasdaq. The offering is expected to close on January 30, 2023, subject to satisfaction of customary closing conditions.

Genelux Corporation Initiates a Pivotal Phase 3 Trial, Evaluating Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer

- The Company's first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapy
- Trial will be conducted as a collaboration between Genelux and The Gynecological Oncological Group (GOG)

Sept. 21, 2022 -- Genelux Corporation announced that it has initiated OnPrime, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer (PRROC).

OnPrime is a US-based trial that will be conducted at approximately 30 sites across the country and has a planned enrollment of 186 women with PRROC, randomized 2:1 into an Experimental Arm of Olvi-Vec and platinum-doublet + bevacizumab and an Active Comparator Arm of platinum-doublet + bevacizumab.

To date, Olvi-Vec has been studied in multiple early- and mid-phase clinical trials via regional, local and systemic deliveries, as a monotherapy and in combination with other therapies, in approximately 150 patients with a variety of cancer types. In the VIRO-15 Phase 2 trial, twenty-seven PRROC patients with a median of four prior lines and disease progressed after the last prior line, were enrolled. Olvi-Vec met the pre-established efficacy and safety endpoints as shown in data presented in an Oral Plenary Session at the International Gynecologic Cancer Society 2020 Annual Global Meeting. Median progression-free survival by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 was 11.0 months (95% CI, 6.7-13.0 months), overall response rate (ORR) by RECIST1.1 was 54%, and ORR by GCIG CA-125 was 85%. The most frequent grade 3 treatment-related adverse event was abdominal pain (7.4%), with no observed treatment-related discontinuations or patient deaths. Our clinical trials have yielded data that has informed future clinical strategy and trial design involving multiple indications and methods of delivery.

OnPrime Study eligibility: Eligible patients will have a minimum of 3 prior lines of therapy, but there is no limitation on the maximal number of prior therapies. The primary endpoint is progression-free survival based on RECIST 1.1 as assessed by a blinded independent central review, with overall response rate, overall survival and safety as key secondary endpoints.

Genelux Announces Exclusive Out-Licensing Agreement with ELIAS Animal Health for V-VET1, a Proprietary Oncolytic Vaccinia Virus Treatment for Pets with Various Cancers

- V-VET1, a clinical-stage animal health-specific product candidate, is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis)
- Terms of the agreement grant ELIAS the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment of cancer in veterinary medicine

Nov. 18, 2021 -- Genelux Corporation announced an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health, a biotechnology company advancing its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis).

ELIAS Animal Health plans future clinical trials to evaluate and develop V-VET1 as a potential new immunotherapy option for veterinary oncologists. Under the terms of the agreement, Genelux will receive an upfront payment, development and sales milestones, and royalties on product sales.

Genelux conducted a Phase 1 study in which V-VET1 was administered to canines with several different types of cancer, including mast cell tumors, osteosarcoma, soft tissue sarcoma, anal gland carcinoma and T-cell lymphoma. No maximum tolerated dose was reached in this dose-escalation trial and dogs tolerated their infusions well. Evidence of antitumor responses and of disease control were observed.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Genelux Corporation
NASDAQ: GNLX

www.GENELUX.com

Barwicki Investor Relations * 30 Wall Street, 8 FL * New York, NY 10005

Deliver to: